BIOCRYST PHARMACEUTICALS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
- Conditions
- Cutaneous T-cell Lymphoma (CTCL),
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT00501735
- Locations
- ๐บ๐ธ
Gabrail Cancer Center, Canton, Ohio, United States
๐ซ๐ทCreteil, Creteil, France
๐ซ๐ทHopital Hotel-Dieu, Clermont-Ferrand, France
Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
- Conditions
- Influenza
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00486980
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT00453999
- Locations
- ๐บ๐ธ
Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
๐บ๐ธWashington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00419081
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธNew York Medical College Division of Oncology, Valhalla, New York, United States
๐บ๐ธLiberty Hematology and Oncology, Columbia, South Carolina, United States
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 344
- Registration Number
- NCT00419263
- Locations
- ๐จ๐ฆ
Manna Research, Toronto, Ontario, Canada
๐บ๐ธPrimary Physicians Research, Inc, Pittsburgh, Pennsylvania, United States
๐บ๐ธBaylor Clinic-Baylor College of Medicine, Houston, Texas, United States
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Leukemia, Lymphocytic, Chronic
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00289549
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00289562
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00098332
- Locations
- ๐บ๐ธ
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
๐บ๐ธM.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
๐บ๐ธLurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
- Conditions
- Leukemia, T-Cell
- First Posted Date
- 2004-11-04
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00095381
- Locations
- ๐บ๐ธ
Weil Medical College of Cornell University, New York, New York, United States
BCX-1777 in Treating Patients With Refractory Cancer
- Conditions
- Cancer
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00073944
- Locations
- ๐บ๐ธ
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States